ArticleEchocardiography (Mount Kisco, N.Y.)2026
Echocardiographic Pulmonary-Left Atrial Ratio and Epicardial Adipose Tissue as Noninvasive Markers of Obstructive Sleep Apnea.
Article in Echocardiography (Mount Kisco, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObstructive sleep apnea syndrome (OSAS) is linked to pulmonary hypertension and cardiovascular risk, yet simple echocardiographic indices related to cardiopulmonary hemodynamics and cardiometabolic burden are limited. We evaluated ePLAR and epicardial adipose tissue (EAT) thickness as complementary, noninvasive echocardiographic markers associated with OSAS presence and severity in newly diagnosed patients.
methodsIn this cross-sectional study, 63 polysomnography-confirmed OSAS patients and 63 controls with a similar distribution of age, sex, and major comorbidities underwent transthoracic echocardiography. OSAS severity was classified as mild, moderate, or severe. ePLAR (TRVmax/E/e') and EAT were measured. Diagnostic performance was assessed by ROC analysis (apparent discrimination), and prediction models for severe OSAS were fitted using Firth penalized logistic regression with bootstrap optimism correction.
resultsOSAS patients had higher EAT (0.62 ± 0.11 vs. 0.53 ± 0.06 cm) and ePLAR (0.37 ± 0.09 vs. 0.23 ± 0.04 m/s) than controls (both p < 0.001). Within OSAS, both measures increased stepwise with severity (p < 0.001). In internally validated models, adding ePLAR and/or EAT to age/sex/BMI improved discrimination for severe OSAS.
conclusionsEPLAR and EAT were associated with OSAS presence and severity and showed good apparent discrimination for severe OSAS in this cohort; these findings are hypothesis-generating and require external validation in clinically representative populations before any clinical implementation.
trial registrationThis study was observational and cross-sectional in design and was not registered in a clinical trial registry because it was not an interventional clinical trial.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.